Delaware to Regulate Multi-Billion-Dollar Pharmacy Benefit Manager Industry, Protecting Consumers and Local Businesses
Department of Insurance will lead effort to rein in monopolistic behavior and excessive pharmaceutical costs Insurance Commissioner Trinidad Navarro announced today that the Delaware Department of Insurance will begin the process of building and enforcing regulations regarding Pharmacy Benefit Managers (PBMs) as a new law goes into effect. The new authorities of the department will […]
Delaware will hold its 20th Prescription Drug Take-Back Day on Saturday, April 24, 2021. Delawareans can discard their expired or unused medications at 26 locations statewide between 10:00 a.m. and 2:00 p.m. Organized nationally by the Drug Enforcement Administration (DEA), National Prescription Drug Take-Back Day is operated locally by the Division of Public Health (DPH). […]
DOVER, DE – All Delaware prescribers and pharmacists can now integrate their electronic health record and pharmacy management systems with the state’s prescription monitoring program (PMP), the Delaware Division of Professional Regulation has announced. The integration will be via Appriss Health’s PMP Gateway solution. Appriss Health has delivered PMP services for the Delaware Division of […]
One year after new regulations issued, Delaware opioid prescriptions and quantities dispensed continue to drop
The number of prescriptions for opioid medications in Delaware, as well as the total quantity of opioids dispensed, have dropped significantly in the 12 months since the Department of State enacted stricter prescribing regulations to help combat the opioid crisis statewide.
51 Attorneys General Reach Consumer Protection Settlement with Boehringer Ingelheim Pharmaceuticals, Inc. Concerning Off-Label Promotion of Four Prescription Drugs
Delaware and the attorneys general of 49 other states and the District of Columbia have reached a settlement with Boehringer Ingelheim Pharmaceuticals, Inc. (“BIPI”) regarding alleged off-label marketing and deceptive and misleading representations made in BIPI’s promotion of four of its prescription drugs: Micardis®, Aggrenox®, Atrovent®, and Combivent®. The settlement resolves allegations that BIPI engaged […]